Skip to content


  • Original
  • Open Access

Treatment satisfaction with zolmitriptan nasal spray for migraine in a real life setting: results from phase two of the REALIZE study

  • 1Email author,
  • 2,
  • 3,
  • 4 and
The Journal of Headache and Pain20056:237

  • Received: 24 March 2005
  • Accepted: 7 July 2005
  • Published:


In phase one of the REALIZE study, zolmitriptan nasal spray demonstrated a significant headache response from 10 min post–dose and total symptom relief from 30 min post–dose. The objective of phase two was to investigate patients' dosing patterns, satisfaction and preference following openlabel treatment with the nasal spray. Up to 3 attacks were treated. The ITT population consisted of 851 patients. The median time from onset of symptoms to treatment was 1 h 15 min (primary endpoint). Most patients reported being satisfied or very satisfied with zolmitriptan nasal spray (75.7%). Furthermore, the majority of patients would be willing to use zolmitriptan nasal spray in the future (59.8%) and preferred zolmitriptan nasal spray over previous therapies (57.8%). Zolmitriptan nasal spray was well tolerated. Most patients were satisfied with zolmitriptan nasal spray, were willing to continue using it and preferred it to previous therapies.

Key words

  • Migraine
  • Zolmitriptan
  • Intranasal
  • Satisfaction


By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate. Please note that comments may be removed without notice if they are flagged by another user or do not comply with our community guidelines.